Suppression of TNFalpha and IL-12 in therapy
AssigneeThe Kennedy Institute of Rheumatology
InventorsMarc Feldmann, Anne-Marie Malfait, Debra Butler, Fionula Brennan, Ravinder Maini
Life of this patent
Estimating the term…
Abstract
Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed are compositions comprising a TNF antagonist and an IL-12 antagonist. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.
Claims2
1-32. (canceled)
A method of treating an individual in need of treatment for arthritis which comprises co-administering to the individual an anti-tumor necrosis factor antibody or a fragment thereof which binds to tumor necrosis factor and an anti-interleukin-12 antibody or a fragment thereof which binds to interleukin-12, the amounts of such antibodies being effective to suppress clinical symptoms associated with arthritis in an individual.
Dependencies are inferred from the claim text.